Research Article

Effect of Acute Myocardial Infarction on a Disintegrin and Metalloprotease with Thrombospondin Motif 13 and Von Willebrand Factor and Their Relationship with Markers of Inflammation

Abeer A. Al-Masri,1 Syed Shahid Habib2,1 Ahmad Hersi,2 and Hana Al Zamil1

1Department of Physiology, College of Medicine, King Khalid University Hospital, King Saud University, Riyadh, Saudi Arabia
2Department of Cardiac Sciences, College of Medicine, King Khalid University Hospital, King Saud University, Riyadh, Saudi Arabia

Correspondence should be addressed to Syed Shahid Habib; shahidhabib44@yahoo.com

Received 7 October 2019; Revised 26 November 2019; Accepted 29 November 2019; Published 11 February 2020

Academic Editor: Mario Zuccarello

Copyright © 2020 Abeer A. Al-Masri et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objectives. Coagulation mechanisms and fibrinolytic assembly are important components role players of acute myocardial infarction (AMI) progression. Our study objective was to see the serial variations in the levels of Von Willebrand factor (VWF) and A Disintegrin and Metalloprotease with ThromboSpondin motif (ADAMTS13) over the course of AMI and to determine their relationship with the cardiovascular risk markers and the patient’s clinical characteristics.

Methods. This project was done at the departments of Emergency Medicine, Physiology and Cardiac sciences of King Saud University Medical City. We studied ADAMTS13, VWF, fibrinogen, and CRP levels in 80 patients with AMI when patients were admitted; post AMI by 3-4 days and at follow-up of 3 months. We compared them with a control group consisting of 36 subjects.

Results. AMI had significantly lower levels of ADAMTS13 at AMI and post 3-4 days; at follow-up the difference in levels was nonsignificant, when compared with controls. Similarly, VWF levels were significantly higher in AMI and remained high even at follow-up compared to control subjects. VWF/ADAMTS13 ratio was also significantly higher at AMI and 3-4 days while at follow-up difference was nonsignificant compared to control subjects. Regression analysis between hsCRP and ADAMTS13 showed an inverse relationship ($r = 0.376$, $p < 0.01$), while correlation with VWF was significantly positive ($r = 0.337$, $p < 0.01$).

Conclusions. Increased levels of VWF and reduced levels of ADAMTS13 activity may contribute to the pathogenesis of acute myocardial infarction and might prove to be important mediators of AMI progression.

1. Introduction

Coagulation assembly and its fibrinolytic components are the leading cause of mortality worldwide and has estimated management burden of higher than $250$ billion that is expected to be tripled by the year 2030 [1]. In addition management of thrombotic and haemorrhagic attacks may add to increase incidence and cost of management of coagulation disorders [2].

The vascular endothelium is a primary source of several very essential agents that participate in cardiovascular pathophysiology. The VWF is synthesised in endothelial cells and is then stored. It mediates platelet aggregation and adhesion [3]. It carries factor VIII in circulation and mediates initial platelets that stick to the sub endothelium following vascular endothelial damage as a result of hyperlipidaemia, smoking, or hypertension [4, 5].

Several factors can affect the levels and function of VWF like blood group, inflammatory state, and proteolytic activity of ADAMTS13 [6]. Tyrosine-842 and methionine-843 bonding is cleaved by ADAMTS13 in the VWF multimers domain A2, resulting in two 140 and 176 kDa portions. The 2 fragments behave less actively in aggregation of platelets than the uncleaved VWF multimers [7, 8].

Different studies suggested that high VWF levels cause endothelium dysfunction and damage caused to it can be an important thrombotic and atherosclerotic marker. A recent meta-analysis reported that plasma VWF was significantly...
increased after onset of AMI until 24 h and persisted high for one week. The levels were reduced to normal at fourteenth day after AMI. They suggested that the changing kinetics of plasma VWF after AMI might provide a new insight in monitoring AMI progression [9]. The highest VWF quartile has been reported to predict the highest risk for fatal and nonfatal CV events and has independent prognostic value compared to intracellular adhesion molecules [10]. In a very recent report the functional effect of the VWF C4 domain for VWF-mediated platelet aggregation was explored and showed that it acted in a shear-dependent manner to lead to AMI. This provided the first ever evidence that a functional variant of VWF is playing a role in arterial thromboembolism [11]. Another study demonstrated that higher VWF/ADAMTS13 ratio may be a significant predictor for adverse cardiovascular episodes after AMI [12]. Therefore, we aimed to examine serial changes in plasma ADAMTS13 antigen and VWF levels after AMI progression and to determine their relationship with the cardiovascular risk markers and the patient’s clinical characteristics.

2. Methods

2.1. Study Design and Settings. This study project was conducted at the department Emergency, Physiology, and Cardiac sciences of King Saud University Medical city (KSUMC). It is a prospective study. This study was approved by institutional review board of KSUMC. Inclusion criteria were adult patients of already diagnosed with AMI according to American Heart Association, guidelines and we used standard criteria as reported [13]. Furthermore, individuals with concomitant systemic diseases and critically illness, recent infections, and surgical procedure in past 12 weeks were excluded.

We studied ADAMTS13, VWF, fibrinogen, and CRP levels in 80 patients with AMI during different time frames; when patients were admitted, post AMI by 3-4 days and at follow-up of 3 months. We compared them with a control group consisting of 36 subjects who were matched for gender, age, and body mass index (BMI). They were free of any clinical manifestations of coronary, peripheral or cerebral artery disease by detailed relevant history, clinical examination, and had normal electrocardiographic findings.

2.2. Analytical Details and Assays. Overnight fasting Venous blood samples were collected and analysed for blood lipids including serum total cholesterol (TC), serum High density lipoprotein (HDL), serum Triglycerides (TG), and serum Low density Lipoprotein (LDL) by colorimetry enzymatic assay, (Dimension, USA). hsCRP assays were done by turbidimetry (Quantex hsCRP ultra sensitive kits, by BIOKIT Spain). American Heart Association has published guidelines for measurement, evaluation, and risk levels of hsCRP which were used in our study [14]. ADAMTS13 levels in plasma were estimated by sandwich ELISA Human ADAMTS13 ELISA kits by American Diagnostica Inc., USA.

2.2.1. Statistical Analysis. For data entry and analysis Statistical Package for Social Sciences (SPSS) version 20.0, was used.

Table 1: Clinical and demographic data of control and patients with AMI.

|               | Control N = 36 | AMI N = 50 | p values |
|---------------|---------------|------------|----------|
| M/F           | 20/16         | 32/18      |          |
| Age           | 52.40 ± 8.62  | 54.83 ± 12.72 | 0.2282 |
| BMI           | 26.41 ± 3.58  | 28.27 ± 6.21 | 0.2645 |
| SBP mmHg      | 126.27 ± 3.25 | 131.97 ± 20.75 | 0.1170 |
| DBP mmHg      | 75.35 ± 2.13  | 76.87 ± 14.65 | 0.5416 |
| Fibrinogen    | 329.32 ± 60.72 | 425.09 ± 148.72 | 0.0383 |
| VWF µIU/L     | 12.56 ± 4.18  | 14.31 ± 3.88  | 0.0435 |
| ADAMTS13 µIU/L| 24.22 ± 5.59  | 23.11 ± 5.11  | 0.5699 |
| hsCRP mg/dl   | 0.28 ± 0.32   | 0.64 ± 0.75  | 0.0051 |
| TC mmol/L     | 4.48 ± 0.60   | 4.37 ± 1.32  | 0.7492 |
| TG mmol/L     | 1.11 ± 0.49   | 1.78 ± 1.03  | 0.012 |
| LDL mmol/L    | 2.76 ± 0.53   | 2.82 ± 1.11  | 0.8423 |
| HDL mmol/L    | 1.07 ± 0.32   | 0.75 ± 0.23  | 0.0012 |

Data is expressed as Mean ± SD. Systolic blood pressure (SBP), Diastolic Blood pressure (DBP), Differences were studied by Mann Whitney test for Fibrinogen, VWF, ADAMTS13 and hsCRP while Independent Student’s t test for other parameters. Reference values for blood analytes: TC: <1.7 mmol/L, TG: <1.7 mmol/L, LDL: <2.3 mmol/L, HDL: >1.5 mmol/L; Fibrinogen: 150-400 mg/dl, hsCRP mg/dl: (Low <.1, Average .1–.3, High >.3).

Descriptive characteristics and the lipid profile of the study patients were expressed as Mean ± SD (Standard Deviation). Kolmogorov–Smirnov and Shapiro–Wilks tests were used to see that data is following normal distribution or not. Those parameters which were not following normal distribution were analysed by nonparametric Mann Whitney test. For multiple group comparisons ANOVA was used for normally distributed data and Kruskal Wallis test for skewed data. Spearman’s correlations were determined between Gensini score of CAD severity, vessel scores, hsCRP and lipids. p-value of <0.05 was taken as significant.

3. Results

Patients with AMI showed significantly higher levels of fibrinogen and VWF levels compared to the control group (p < 0.01) as shown in Table 1. ADAMTS13 levels were significantly lower at AMI and after 3-4 days, while at follow-up levels the difference was nonsignificant (Figure 1). VWF levels significantly increased after AMI and remained high even at follow-up compared to control subjects (Figure 2). VWF/ADAMTS13 ratio was also significantly higher at AMI and 3-4 days while at follow-up difference was nonsignificant compared to control subjects (Figure 3). Spearman’s correlations were determined between Gensini score of CAD severity, vessel scores, hsCRP and lipids. p-value of <0.05 was taken as significant. Table 2 shows correlation analysis of ADAMTS13, VWF and VWF/ADAMTS13 ratio with demographic characteristics, lipid profile, Gensini score of CAD severity, vessel scores and hsCRP. It was observed that BMI (r = .287, p < 0.05) correlated positively with ADAMTS13. LDL correlated
negatively with ADAMTS13 \((r = -0.333, \ p < 0.05)\), while it correlated positively with VWF \((r = 0.374, \ p < 0.01)\) and VWF/ADAMTS13 ratio \((r = 0.296, \ p < 0.01)\). Triglycerides correlated negatively with VWF \((r = -0.291, \ p < 0.05)\) and VWF/ADAMTS13 ratio \((r = -0.256, \ p < 0.05)\). HDL levels correlated negatively with VWF \((r = -0.297, \ p < 0.05)\). The levels of hsCRP correlated positively with VWF/ADAMTS13 ratio \((r = 0.340, \ p < 0.01)\). All other correlations were not significant.

4. Discussion

In this study, we are reporting serial variations in VWF and ADAMTS13 after AMI and as it progresses. Moreover, their relationship between the plasma titers and the patient’s clinical data. Compared to control subjects patients with AMI had significant changes in levels of both ADAMTS13 and VWF, even with their VWF/ADAMTS13 ratio titers at AMI, after 3–4 days and at follow-up. In a previously published work results showed inverse correlation between ADAMTS-13 and VWF, although, sample size was relatively small yet the effect was more significant after acute release of VWF. The same trend was observed in our study also [15]. Crawley JTB et al. have shown positive correlation of VWF with fibrinogen, showing that it may behave as acute-phase reactant. In our study, there was negative associations between ADAMTS13 and hsCRP [16].
An interesting recent study has reported reduced ADAMTS13 in patients with AMI and they used data from samples taken on hospital admission. Consequently, whether reduced ADAMTS13 was a cause or effect of MI in those individuals could not be determined. Our study gives an evidence that it may be the cause of AMI because at follow-up levels it became normal [17]. In line with our study it is also reported that decrease in ADAMTS13 and increase in titers of VWF lead to a higher risk of ischemia induced stroke and AMI. Oral contraceptives further increased this risk in women [18]. Moreover, we have reported recently that lower titers of ADAMTS13 have been associated with a higher mortality in septic shock patients. It was a better comparable predictor to the well-known standard score of Acute Physiology and Chronic Health Evaluation II (APACHE II) for prediction of mortality [19].

The immediate rise in VWF in acute coronary syndrome (ACS) is associated with adverse outcomes [20, 21]. In a prospective longitudinal observational study by Green D et al., it was found that 10 months prior to the heart attacks, median values for VWF and the ratio of VWF and ADAMTS13 were higher in cases than in controls. And there was a significant trend toward an increase in the ratio prior to a cardiovascular event [22]. Masakazu et al., revealed that platelet thrombus formation is the result of a derangement between ADAMTS13 balance and VWF in plasma, and also revealed a pivotal role of ADAMTS13 in platelet stickiness. It is regulated through its inhibitory effect of abnormally large multimers of VWF during normal flowing states. VWF antigen/ADAMTS13 ratio has a significant prognostic power at different time points after heart attacks concomitant with higher chances of adverse outcomes in clinical practise, like heart failure and thrombosis [23].

In unstable angina (UA) patients with the tendency of thrombogenicity increases if the proportion between VWF and ADAMTS13 changes significantly. In unstable angina patients ADAMTS13 were lower compared with stable angina and showed an inverse correlation between ADAMTS13 and VWF. All these observations are consistent with our results in AMI patients. Similar to our results the antigen levels after about six months follow-up became nonsignificant when compared with UA patients in acute phase [24]. The limitations of our study are a relatively small number of samples and short duration. Long term prospective trials at large scale are required to explore the predictive role of VWF and ADAMTS13 in cardiovascular diseases.

5. Conclusions

Our data suggest that increased levels of VWF and reduced levels of ADAMTS13 activity may contribute to the pathogenesis of acute myocardial infarction. These markers might provide a new insight in monitoring progression of AMI.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request both in excel and SPSS format.

Conflicts of Interest

No conflicts are declared with any funding authority or drug industry.

Authors’ Contributions

Abeer A. Al-Masri, Syed Shahid Habib, Ahmad Hersi and Hana Al Zamil performed patient selection, data collection, statistical analysis and manuscript writing. Abeer A. Al-Masri and Syed Shahid Habib designed the study, performed the statistical analysis and wrote the manuscript. Hana Al Zamil and Syed Shahid Habib contributed to data analysis, revision and final approval of manuscript.

Acknowledgments

The authors thank Mr. Timhar Amlih for his technical support. The authors extend their appreciation to the Deanship of Scientific Research at King Saud University for funding this work through the research group project No. RGP-VPP-016, entitled “Cardiovascular Research Group”.

References

[1] P. A. Heidenreich, J. G. Trogdon, O. A. Khavjou et al., “Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association,” Circulation, vol. 123, no. 8, pp. 933–944, 2011.

[2] A. S. Wolberg, M. M. Aleman, K. Leiderman, and K. R. Machlus, “Procoagulant activity in hemostasis and thrombosis: Virchow’s triad revisited,” Anesthesia and Analgesia, vol. 114, no. 2, pp. 275–85, 2012.

[3] Z. B. Gungor, N. Sipahioglu, H. Sonmez et al., “Endothelial dysfunction markers in low cardiovascular risk individuals: comparison of males and females,” Journal of Medical Biochemistry, vol. 36, no. 1, pp. 62–72, 2017.

[4] Z. B. Gungor, N. Sipahioglu, H. Sonmez et al., “Endothelial dysfunction markers in low cardiovascular risk individuals: comparison of males and females,” Journal of Medical Biochemistry, vol. 36, no. 1, pp. 62–72, 2017.

[5] Z. B. Gungor, N. Sipahioglu, H. Sonmez et al., “Endothelial dysfunction markers in low cardiovascular risk individuals: comparison of males and females,” Journal of Medical Biochemistry, vol. 36, no. 1, pp. 62–72, 2017.

[6] L. Qu, M. Jiang, W. Qiu et al., “Assessment of the diagnostic value of plasma levels, activities, and their ratios of von Willebrand factor and ADAMTS13 in patients with cerebral infarction,” Clinical and Applied Thrombosis/Hemostasis, vol. 22, no. 3, pp. 252–259, 2016.

[7] S. Lancellotti, F. Peyvandi, M. T. Pagliari et al., “The D173G mutation in ADAMTS-13 causes a severe form of congenital thrombotic thrombocytopenic purpura. A clinical, biochemical and in silico study,” Thrombosis and Haemostasis, vol. 115, no. 1, pp. 51–62, 2016.

[8] C. U. Rank, J. Kremer Hovinga, M. M. Taleghani, B. Lämmlle, J. P. Götzte, and O. J. Nielsen, “Congenital thrombotic thrombocytopenic purpura caused by new compound heterozygous mutations of the ADAMTS13 gene,” European Journal of Haematology, vol. 92, no. 2, pp. 168–171, 2014.
[9] X. Wang, J. Zhao, Y. Zhang et al., "Kinetics of plasma von Willebrand factor in acute myocardial infarction patients: a meta-analysis," *Oncotarget*, vol. 8, no. 52, pp. 90371–90379, 2017.

[10] J. Dong, Y. J. Li, Z. K. Yang, and R. Xu, "Prognostic value of serum von Willebrand factor, but not soluble ICAM and VCAM, for mortality and cardiovascular events is independent of residual renal function in peritoneal dialysis patients," *Peritonal Dialysis International*, vol. 34, no. 7, pp. 706–713, 2014.

[11] R. Schneppenheim, N. Hellermann, M. A. Brehm et al., "The von Willebrand factor Tyr2561 allele is a gain-of-function variant and a risk factor for early myocardial infarction," *Blood*, vol. 133, no. 4, pp. 356–365, 2019.

[12] K. Kaikita, K. Soejima, M. Matsukawa, T. Nakagaki, and H. Ogawa, "Reduced von Willebrand factor-cleaving protease (ADAMTS13) activity in acute myocardial infarction," *Journal of Thrombosis and Haemostasis*, vol. 4, no. 11, pp. 2490–2493, 2006.

[13] P. Tricoci, L. K. Newby, R. M. Clare et al., "Prognostic and practical validation of current definitions of myocardial infarction associated with percutaneous coronary intervention," *JACC: Cardiovascular Interventions*, vol. 11, no. 9, pp. 856–864, 2018.

[14] Z. A. Al Aseri, S. S. Habib, and A. Marzouk, "Predictive value of high sensitivity C-reactive protein on progression to heart failure occurring after the first myocardial infarction," *Vascular Health and Risk Management*, vol. 15, no. 15, pp. 221–227, 2019.

[15] P. M. Mannucci, C. Capoferri, and M. T. Canciani, "Plasma levels of von Willebrand factor regulate ADAMTS-13, its major cleaving protease," *British Journal of Haematology*, vol. 126, no. 2, pp. 213–218, 2004.

[16] J. T. B. Crawley, D. A. Lane, M. Woodward, A. Rumley, and G. D. O. Lowe, "Evidence that high von Willebrand factor and low ADAMTS-13 levels independently increase the risk of a nonfatal heart attack," *Journal of Thrombosis and Haemostasis*, vol. 6, no. 4, pp. 583–588, 2008.

[17] B. Rutten, A. Maseri, D. Cianflone et al., "Plasma levels of active Von Willebrand factor are increased in patients with first ST-segment elevation myocardial infarction: a multicenter and multiethnic study," *European Heart Journal: Acute Cardiovascular Care*, vol. 4, no. 1, pp. 64–74, 2015.

[18] H. M. Andersson, B. Siegerink, B. M. Luken et al., "High VWF, low ADAMTS13, and oral contraceptives increase the risk of ischemic stroke and myocardial infarction in young women," *Blood*, vol. 119, no. 6, pp. 1555–1560, 2012.

[19] M. F. Azfar, M. F. Khan, S. S. Habib et al., "Prognostic value of ADAMTS13 in patients with severe sepsis and septic shock," *Clinical and Investigative Medicine*, vol. 40, no. 2, pp. E49–E58, 2017.

[20] K. W. Lee, G. Y. Lip, M. Tayebjee, W. Foster, and A. D. Blann, "Circulating endothelial cells, von Willebrand factor, interleukin-6, and prognosis in patients with acute coronary syndromes," *Blood*, vol. 105, no. 2, pp. 526–532, 2005.

[21] J. P. Collet, G. Montalescot, E. Vicaut et al., "Acute release of plasminogen activator inhibitor-1 in ST-segment elevation myocardial infarction predicts mortality," *Circulation*, vol. 108, no. 4, pp. 391–394, 2003.

[22] D. Green, L. Tian, P. Greenland et al., "Association of the von Willebrand factor-ADAMTS13 ratio with incident cardiovascular events in patients with peripheral arterial disease," *Clinical and Applied Thrombosis/Hemostasis*, vol. 23, no. 7, pp. 807–813, 2017.

[23] M. Matsukawa, K. Kaikita, K. Soejima et al., "Serial changes in von Willebrand factor-cleaving protease (ADAMTS13) and prognosis after acute myocardial infarction," *The American Journal of Cardiology*, vol. 100, no. 5, pp. 758–763, 2007.

[24] S. Fuchigami, K. Kaikita, K. Soejima et al., "Changes in plasma Von Willebrand factor-cleaving protease (ADAMTS13) levels in patients with unstable angina," *Thrombosis Research*, vol. 122, no. 5, pp. 618–623, 2008.